Jaguar Health Poised for Breakthrough with Crofelemer Trials
AI Prediction of Jaguar Health, Inc. (JAGX)
Jaguar Health Inc. is positioned to experience significant growth due to its innovative pharmaceutical developments, particularly in the treatment of gastrointestinal distress for both humans and animals. This growth is anticipated to be driven by the ongoing clinical trials and expected regulatory milestones. With a focus on underserved medical needs and a sustainable sourcing strategy, Jaguar Health may see an increase in investor interest as these catalysts come to fruition.
Jaguar Health Inc., a commercial-stage pharmaceutical company, specializes in developing plant-based prescription medicines for gastrointestinal distress. Their flagship product, Mytesi, used for treating noninfectious diarrhea in adults with HIV/AIDS, alongside their veterinary products like Canalevia for dogs, showcases their diversified approach to healthcare solutions. Recently, the company has been actively pursuing clinical trials for crofelemer in new indications including rare diseases like Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS). The potential approval and commercialization of these indications represent significant market opportunities. Furthermore, Jaguar Health's strategy includes expanding its footprint in the cancer supportive care market, which could enhance its revenue streams and market share. The anticipated data from their clinical trials and subsequent FDA interactions are expected to be critical catalysts for the company's stock in the near term.
JAGX Report Information
Prediction Date2025-07-07
Close @ Prediction$2.58
Mkt Cap3m
IPO Date2015-05-13
AI-derived Information
Recent News for JAGX
- Mar 3, 9:00 am — Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 (ACCESSWIRE)
- Feb 18, 9:00 am — Jaguar Health Announces a Special One-time Stock Dividend (ACCESSWIRE)
- Jan 22, 9:00 am — Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi (ACCESSWIRE)
- Jan 16, 1:54 pm — The Surge In Jaguar Health Stock: What's Happening Now? (Benzinga)
- Jan 14, 9:00 am — Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts (ACCESSWIRE)
- Jan 12, 9:00 am — Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million (ACCESSWIRE)
- Jan 6, 9:00 am — Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication (ACCESSWIRE)
- Jan 2, 9:00 am — Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
- Dec 15, 9:00 am — Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (ACCESSWIRE)
- Dec 10, 9:00 am — FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
- Dec 8, 4:15 pm — Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders (ACCESSWIRE)
- Dec 2, 9:00 am — Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study (ACCESSWIRE)
NDAPR events for JAGX
-
2026-03-03 14:07Revision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Additional non-dilutive funding supports ongoing crofelemer development and commercialization efforts.
-
2026-02-18 14:05Revision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The dividend announcement does not fundamentally alter the company's clinical or financial trajectory.
-
2026-01-22 14:56Revision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Recent non-dilutive funding enhances Jaguar's financial position, supporting ongoing rare disease pipeline advancements.
-
2026-01-19 09:03Revision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: New licensing deal likely to boost investor confidence and stock price.
-
2026-01-14 14:04Revision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: The news of the upcoming presentation does not materially alter the investment thesis.
-
2026-01-06 23:39Revision: NO_CHANGE | Price Pressure Direction: YES_UP | Thesis Unchanged?: YES_UNCHANGEDRationale: Positive clinical trial results reinforce the bullish outlook and potential FDA expedited approval.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.